Integrated operating frameworks are displacing fragmented vendor ecosystems, enabling faster launch readiness, omnichannel ...

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...

DTP functions as an “affordability waterfall,” dynamically routing patients to MFN cash pricing, commercial insurance, or ...

Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski, vice president, strategic market ...

In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, discusses how and why ...

Shareholder approval positions Garijo to steer strategy toward operational rigor, portfolio discipline, and more consistent ...

Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...

In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...

ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene ...